BioVersys' AlpE Combination Shows Promising TB Treatment Results in Phase 2a Trial

Event summary

  • BioVersys' Phase 2a trial of AlpE (alpibectir + ethionamide) for tuberculosis showed promising clinical proof of concept in a 7-day early bactericidal activity (EBA) study.
  • Results published in the New England Journal of Medicine on February 19, 2026, highlight AlpE's potential to overcome drug resistance in TB treatment.
  • The trial, conducted in South Africa, was supported by multiple EU grants and public-private partnerships, including EDCTP2 and IMI2.
  • BioVersys plans to initiate a Phase 2 trial for meningeal TB later in 2026 and continue Phase 2 studies in the UNITE4TB project with GSK.

The big picture

BioVersys' AlpE combination represents a novel approach to tackling drug-resistant tuberculosis, a global health crisis with 1.23 million deaths in 2024. The positive Phase 2a results position AlpE as a potential replacement for isoniazid in first-line regimens or an addition to future TB treatment protocols. The collaboration with GSK and other partners underscores the strategic importance of addressing antimicrobial resistance through innovative public-private initiatives.

What we're watching

Clinical Progression
Whether AlpE can maintain its promising efficacy signals in larger Phase 2 trials, particularly in meningeal TB.
Regulatory Pathway
The pace at which regulatory approvals could be sought, given the unmet need in TB treatment.
Partnership Dynamics
How BioVersys and GSK will structure further development and potential commercialization of AlpE.